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Abstract
Background: Chronic kidney disease (CKD) is a global health burden, yet it is still underrepresented within public
health agendas in many countries. Studies focusing on the natural history of CKD are challenging to design and
conduct, because of the long time-course of disease progression, a wide variation in etiologies, and a large amount
of clinical variability among individuals with CKD. With the difference in health-related behaviors, healthcare delivery,
genetics, and environmental exposures, this variability is greater across countries than within one locale and may not
be captured effectively in a single study.
Methods: Studies were invited to join the network. Prerequisites for membership included: 1) observational designs
with a priori hypotheses and defined study objectives, patient-level information, prospective data acquisition and
collection of bio-samples, all focused on predialysis CKD patients; 2) target sample sizes of 1,000 patients for adult
cohorts and 300 for pediatric cohorts; and 3) minimum follow-up of three years. Participating studies were surveyed
regarding design, data, and biosample resources.
Results: Twelve prospective cohort studies and two registries covering 21 countries were included. Participants age
ranges from >2 to >70 years at inclusion, CKD severity ranges from stage 2 to stage 5. Patient data and biosamples
(not available in the registry studies) are measured yearly or biennially. Many studies included multiple ethnicities;
cohort size ranges from 400 to more than 13,000 participants. Studies’ areas of emphasis all include but are not limited
to renal outcomes, such as progression to ESRD and death.
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Conclusions: iNET-CKD (International Network of CKD cohort studies) was established, to promote collaborative
research, foster exchange of expertise, and create opportunities for research training. Participating studies have many
commonalities that will facilitate comparative research; however, we also observed substantial differences. The diversity
we observed across studies within this network will be able to be leveraged to identify genetic, behavioral, and health
services factors associated with the course of CKD. With an emerging infrastructure to facilitate interactions among the
investigators of iNET-CKD and a broadly defined research agenda, we are confident that there will be great opportunity
for productive collaborative investigations involving cohorts of individuals with CKD.
Keywords: Cohort study, Network, CKD, Epidemiology, Diversity
Abbreviations: ABI, Ankle-brachial index; ABPM, Ambulatory blood pressure monitoring; AT, Austria; CA, Canada;
CH, Switzerland; CKD, Chronic kidney disease; CZ, Czech Republic; DE, Germany; ECG, electrocardiogram;
Echocardio, echocardiogram; eGFR, estimated glomerular filtration rate; ESRD, End-stage renal disease; FR, France;
GB, United Kingdom; HU, Hungary; IT, Italy; LT, Lithuania; NL, Netherlands; PL, Poland; PT, Portugal; PWV, Pulse
wave velocity; RS, Serbia; SW, Sweden; TR, Turkey; US, United States
Background
Chronic kidney disease (CKD) represents a large burden
of morbidity across the globe affecting between 10 and
16 % of all adults [1–6]. Importantly, CKD has been
identified to substantially elevate the risk of cardiovascu-
lar disease and mortality [7]. When diagnosed early, pro-
gression of CKD can be delayed, postponing the potent
negative impact of end-stage renal disease (ESRD) on
quality of life and survival. Despite the size of the bur-
den, CKD is under-acknowledged as a public health con-
cern. While it is well recognized that CKD augments the
risk for cardiovascular disease [8], it is often not men-
tioned in public health agendas, thus limiting research
opportunities from public funding agencies.
Because the natural history of CKD is often long, CKD
is challenging to study. Its etiologies are numerous and
some are rare. Outcomes from CKD such as dialysis and
transplantation may take years to occur, and over that
time, intercurrent illness, health behaviors, and environ-
mental exposures may alter its course, accelerate its pro-
gression, and lead to premature death from cardiovascular
disease. Further, there is a large amount of clinical variabil-
ity among individuals with CKD making yet more complex
the design and conduct of clinical studies, with or without
interventions. This variability is yet greater across national
boundaries than within any one locale in light of the
associated variations in health-related behaviors, health-
care delivery, genetics and environmental exposures.
An improved understanding of the natural history of
CKD, of factors associated with its progression and the
occurrence of morbid complications, as well as its im-
pact on quality of life, is urgently required. This detailed
understanding is essential if we are to design robust
interventional studies, and potentially improve the out-
comes of those living with CKD.
Well-designed cohort studies permit rigorous tracking
of individual patients over time. There are numerous
examples of important long-term cohort studies in car-
diovascular disease (Framingham Heart Study, Nurses’
Health Study, etc.). Several large cohort studies have also
collected a limited set of kidney function parameters and
helped us to understand CKD prevalence and associa-
tions between CKD and cardiovascular disease. More re-
cently, a number of cohort studies focused on CKD have
been implemented in different parts of the world. These
prospective studies have many similarities, and in gen-
eral, aim to investigate the factors associated with pro-
gression of CKD and its negative health consequences.
The purpose of this paper is to describe the current
state of these national and regional cohort studies, cur-
rently organized in a ‘virtual‘ network called iNET-CKD,
to form the basis for collaborative research and research
training in CKD. We describe the criteria for member-
ship in this network, contrast the current member stud-
ies, and highlight the types of questions this network is
well-positioned to address.
Methods
History of the network
Building on informal collaborations among the CRIC
study (USA), CKD-JAC (Japan), GCKD (Germany) and C-
Stride (China), members of this network participated in a
2010 NIH-sponsored “inventory meeting” of ongoing
studies of CKD around the globe. A formal call for partici-
pation was organized in 2011, by investigators from CRIC
and GCKD, and leveraging knowledge of other established
cohorts, using some general criteria (listed below). With
facilitation and endorsement by the ISN in 2012, the
iNET-CKD network was formally established.
Goals of the iNET-CKD (Fig. 1)
Collaborative research
Perhaps most important, the network strives to promote
opportunities for joint research involving two or more
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network members. These collaborations include the
work on common research questions, either through
merging of existing data or through joint analyses of
bio-samples. We also hope to increase interest in studies
to validate one another’s findings. This research will per-
mit examination of different patterns of disease around
the globe and expand our understanding of the diversity
of clinical manifestations of CKD.
Exchange of expertise
The second task of this network is to create an atmos-
phere where research groups can provide assistance to
one another for advice and guidance concerning ques-
tions and problems related to study design and imple-
mentation. Shared information at basic levels of study
design, such as data structure and variable definitions,
will enhance the interpretability of analyses integrating
data from multiple cohort studies. Creating an environ-
ment for sharing analytical methods and funding oppor-
tunities will benefit the cohort studies in the network
and promote their ability to extend their scope through
development of ancillary studies. Using web-based com-
munication tools among members of the network, we
will be able to exchange ideas and have access to a web-
site where questions can be posted.
Training
This network also seeks to facilitate training opportun-
ities for young investigators at sites with sufficient infra-
structure to support such training. As well, the network
promotes opportunities for experienced researchers to
visit other network sights as visiting scholars and profes-
sors. Training opportunities offer sustainability and suc-
cession planning to all members, which is essential for
ongoing support.
Criteria for CKD Cohort Inclusion in the iNET-CKD
Through a consensus-building exercise, a set of common
attributes have been defined as prerequisites for mem-
bership into the network. These include: 1) observational
research designs with a priori hypotheses and defined
study objectives, patient-level information, and prospect-
ive data collection including a broad spectrum of CKD-
related health outcomes and bio-samples, all focused on
predialysis CKD patients; 2) a minimum sample size of
1000 patients for adult cohorts and 300 for studies of
children; and 3) a minimum follow-up time of three
years. Not included in the network are studies: 1) that
focus only on ESRD patients; 2) of the general popula-
tion; and 3) that are randomized controlled trials, which
may have targeted highly selected patient groups that
may not represent the larger CKD patient population
(Table 1). As a result, iNET-CKD primarily includes pro-
spective observational studies of predialysis CKD patients;
however, due to the first and second aims mentioned
above, it also facilitates tiered membership levels for
Fig. 1 Three key goals of iNET-CKD
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Observational studies of CKD • ESRD cohorts
▪ Based on a priori hypotheses and
study objectives
• General population cohorts
▪ Study individuals with CKD • Randomized controlled trials
▪ Collect longitudinal data prospectively • Clinical databases
▪ Examine a broad spectrum of
CKD-related health outcomes
▪ Collect and analyze bio-samples
• Sample size ≥1000 in adult studies and
≥300 in pediatric studies
• Duration of follow up ≥3 years
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regional registries of CKD patients or well-designed retro-
spective cohort studies for which all inclusion criteria have
not been met.
Online questionnaire
To catalog participating studies, we sent out an online
survey to 15 prescreened study groups in January 2014,
in addition to scanning published protocols and baseline
papers of each study. The questionnaire included 121
questions about general information of the study design
(e.g. size, locale, duration, goals, and inclusion/exclusion
criteria), baseline demographics (e.g. age, sex, estimated
glomerular filtration rate (eGFR) levels, and availability
of information on socioeconomic status, comorbidities,
and lifestyle risks), laboratory measurements (e.g. avail-
ability and frequency of measurements), sample collec-
tions, imaging studies, and outcome information. Data
from each study’s principal investigator were obtained
electronically. If needed, data were updated through
publications and direct contact with the individual study
groups. Each study was approved by its respective insti-
tutional review boards. No additional approval was ob-
tained to gather summary information for this report, an
activity that involved no additional collection of infor-
mation from study participants.
Results
Participating studies
Principal investigators from 14 studies, including 12 co-
hort studies, responded to the survey and consented to
participation. As a result, the network currently has en-
rolled 14 studies operating in 21 different countries in
Asia, Europe, Australia and North America (Fig. 2).
Some of these cohort studies are still enrolling; hence the
exact number of study participants continues to grow.
Apart from the 12 cohort studies, this network, as men-
tioned above, also includes large registry studies from
Uruguay and Australia, where patients are entered in a
database by healthcare providers who participate in the
National Renal Healthcare Program (NRHP-Uruguay) and
the Queensland Health Renal services, respectively. As of
September 30, 2015, this network included nearly 32,000
patients from cohort studies and 20,000, from registries.
Target populations of the participating studies
Table 2 summarizes the characteristics of the target
population for each study. Some studies have very nar-
row eGFR inclusion ranges. However, it is obvious that
this study group, as a whole, includes CKD patients with
a wide range of renal function. CKiD and the 4C Study
were designed exclusively for pediatric CKD patients.
Both registry-type studies, the CKD.QLD and the
Fig. 2 Participating studies in iNET-CKD. Countries in red represent origin of study. Blue circles represent corresponding sample size. Abbreviations: AT,
Austria; CA, Canada; CH, Switzerland; CZ, Czech Republic; DE, Germany; FR, France; GB, United Kingdom; HU, Hungary; IT, Italy; LT, Lithuania;
NL, Netherlands; PL, Poland; PT, Portugal; RS, Serbia; SW, Sweden; TR, Turkey; US, United States. This figure was obtained courtesy of Microsoft
Office website (https://templates.office.com/en-us/Maps). No additional permission is required for its use
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NRHP-Uruguay, only include adult CKD patients (18 years
or older). Most studies include multiple ethnicities; how-
ever, several such as BIS, CKD-JAC, GCKD, and Triple-A,
only include a single ethnicity. All studies have enrolled
participants from multiple centers that were, in many but
not all cases, academic facilities.
Kidney measures, baseline covariates, and follow-up
intervals
All participating studies have either biennial or annual
follow-up, which includes serum creatinine and urine
albumin-to-creatinine ratios or urine protein-to-creatinine
ratios. Despite lack of standardization of measurements of
common laboratory parameters, calibration may be
achieved through exchange of samples and detailed de-
scriptions of the collection process. All studies have data
on potential confounders of associations between kidney
function and outcomes. Among these are: age, race/ethni-
city, smoking, history of cardiovascular disease, diabetes
mellitus, hypertension status, and body mass index. Fur-
thermore, all studies collect data on medications and all,
except one, on hospitalization. Although major laboratory
parameters, such as serum creatinine and albumin, are be-
ing measured annually in most studies, there is some het-
erogeneity in the data collection with regard to imaging
studies (Table 3). Six studies have collected echocardio-
grams, while two and six studies have collected ankle-
Table 2 Summary table for characteristics of the target populations of participating studies in iNET-CKD
Table 3 Summary table for imaging studies in the participating
studies
Study ECG Echocardio ABI ABPM PWV
BIS - - - + +
CanPREDDICT + + - - -
CKD.QLD - - - - -
CKD-JAC + + + + +
CKD-REIN - + + - -
CKiD - + - + +
CRIC + + + + +
C-STRIDE + + - + +
EQUAL + - - - -
GCKD - - - - +
PROVALID - - - - -
NRHP-Uruguay - - - - -
Triple-A + - - - -
4C Study + + - + +
Abbreviations: ECG electrocardiogram, Echocardio echocardiogram, ABI ankle-
brachial index, ABPM ambulatory blood pressure monitoring, PWV pulse wave
velocity. Note that all of these imaging studies are not
performed systematically
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brachial index (ABI) and pulse wave velocity (PWV) data,
respectively.
Collection of biosamples
Most studies have collected bio-samples. Figure 3 sum-
marizes blood sample collection across the studies, orga-
nized by the type of blood samples preserved and
whether samples are available for further analyses for
harmonization of the laboratory markers or for the
measurement of novel, common biomarkers. Some stud-
ies are preserving buffy coats from which genetic infor-
mation may be extracted, while other studies, such as
CRIC, CKiD, BIS, and GCKD, have already collected
DNA samples for genetic analyses. In CRIC and CKiD,
hair and/or nails have also been collected for chemical
analyses. Blood and urine sample collections have been
done not only at baseline, but also at follow-up visit re-
peatedly in most studies (Table 4).
Outcome variables
All studies collect information on renal outcomes, e.g.
progression to ESRD (initiation of dialysis or kidney
transplantation), doubling of creatinine, as well as car-
diovascular events (myocardial infarction, heart failure,
stroke, etc.), cardiovascular mortality and all-cause mor-
tality (Additional file 1: Table S1). Adjudication of these
outcomes, to some extent, is conducted in each of these
studies, although there is not a uniform method by
which this is done (Additional file 2: Table S2).
Discussion
Commonalities and differences
Participating studies have many commonalities that will
facilitate comparative research. Nevertheless, there are
also major differences. Some have very unrestricted in-
clusion criteria in terms of age, race, and renal function
(e.g. CanPREDDICT, CKD-REIN, and CRIC). Among
these, the CRIC study, however, only includes adult pa-
tients. CKiD, another US-based study, examines CKD
Fig. 3 Graphical summary of blood sample collections in the participating studies. The plus or minus signs following the study names denote the
availability of residual samples for further analyses
Table 4 Summary table for the presence and frequency of
blood and urine samplings
Study Blood Samples Urine Samples
Baseline Follow up Baseline Follow up
BIS + <1/year + <1/year
CanPREDDICT - ≥1/year - ≥1/year
CKD.QLD - - - -
CKD-JAC + ≥1/year + -
CKD-REIN + <1/year + <1/year
CKiD + ≥1/year + ≥1/year
CRIC + ≥1/year + ≥1/year
C-STRIDE + ≥1/year + ≥1/year
EQUAL + ≥1/year + ≥1/year
GCKD + <1/year + <1/year
PROVALID + ≥1/year + ≥1/year
NRHP-Uruguay - - - -
Triple-A + - + -
4C Study + ≥1/year + ≥1/year
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specifically in children ages 1 through 16, which covers
some of the age-range missing in the CRIC study cohort.
On the other hand, BIS, a study based in Berlin, Germany,
only included patients aged ≥70 years. Principally due to
relatively homogenous populations, some studies from
Europe and Asia include only Caucasians (e.g. GCKD) or
Asians (e.g. CKD-JAC or C-STRIDE), while others are
ethnically diverse (e.g. CRIC).
Furthermore, some studies focus on more severe
stages of renal disease. The EQUAL study, based in six
European countries, includes patients with an eGFR of
≤20 ml/min who are 65 years or older. PROVALID, an-
other multi-country study based in Europe, is limited to
investigating renal endpoints in subjects with type 2
diabetes.
Structure
iNET-CKD is an open network. Central coordination is
supported by the ISN, which provides administrative ser-
vices and facilitates linkages with regional boards and pro-
grams, including research programs, training opportunities
amongst others (http://www.theisn.org/initiatives/inet-ckd).
As an international organization committed to linking the
developed and developing world, and to excellence in sci-
ence and education, the ISN is uniquely positioned to
facilitate this initiative, while the leadership of the group
maintains the scientific autonomy for goal-setting within
the group of iNET-CKD participating studies.
Specific features of iNET-CKD as compared with other
CKD consortia
The creation of this iNET-CKD will provide a unique
opportunity for a scientific exchange among CKD inves-
tigators around the globe, as well as to enhance training
opportunities for young researchers. The diversity rep-
resented within the network will facilitate the iden-
tification of yet-unknown factors (genetic, health-related
behaviors, healthcare delivery) associated with the devel-
opment and the course of CKD. Such findings may not
only have implications for clinical care of patients with
CKD but also for health policy makers.
The prospective design of the participating studies is
associated with a high quality of study data and the po-
tential to combine study samples across the network will
enhance the ability to examine multiple health outcomes
related to CKD.
iNET-CKD is not the only network with the goal to ad-
vance research in CKD; there are a number of disease-
specific cohort studies and consortia, such as NEPTUNE
[9] and INSIGHT [10] for nephrotic syndrome and collab-
orative studies on genetic epidemiology in IgA nephropathy
[11], CKD (CKDGen [12]), and pediatric nephrology [13].
However, few studies include a wide range of CKD patients.
The Chronic Kidney Disease Prognosis Consortium (CKD-
PC), established in 2009, is a network of investigators who
have access to a minimum set of data from about fifty co-
horts or clinical trial populations from around the world
drawn from the general-population, populations at high-
risk for kidney disease, and populations with CKD [14].
The ability to process information from a diverse set of
data, using common analytic plans and codes has proven to
be a valuable asset in CKD research studying the prog-
nostic impact of eGFR and albuminuria, as well as es-
tablishing the staging of CKD and helping to revise
practice guidelines [15]. Complementary to the CKD-
PC, iNET-CKD primarily focuses on CKD cohort stud-
ies, involving patients with well-phenotyped CKD using
extensive patient-level data,and biosamples. Rather than
implementing meta-analyses, we seek opportunities to
combine primary data from different groups to imple-
ment joint analyses. Moreover, iNET-CKD focuses on
diverse CKD-related outcomes well beyond progression
of CKD and mortality. The granularity of the collected
data is very high, and biomaterials are available in al-
most all participating cohorts, which present the oppor-
tunity for coordinated analysis of biomarkers, and serve
as an important resource for comparative studies and
validation of findings. Projects in the near future in-
volve observations on international variations in dietary
patterns related to dietary constituents such as phos-
phate and sodium as well as variations in clinical strat-
egies for the management of CKD and their respective
effects on variations in CKD outcomes.
Strengths and limitations
The variation in inclusion criteria is one of the major
strengths of this network. The studied populations are
genetically distinct, which will give insight on possible
genetic determinants of CKD. Furthermore, these popula-
tions also greatly differ with respect to health behaviors,
healthcare delivery, and environments. For example, dif-
ferent utilization of medications may play a role in the
rapidity of progression of CKD in some studies. This net-
work will provide the opportunity to examine the same
ethnicities in multiple countries, providing insights into
the specific role of health behaviors and healthcare deliv-
ery in CKD outcomes.
This network of cohort studies has certain limitations.
While commonalities in study design will facilitate joint
projects, inconsistencies in the definition and capture of
variables as well as adjudication of outcomes can com-
plicate analyses. Second, races and ethnicities, other than
Blacks, Whites and Asians, are underrepresented in our
cohorts. Almost all Blacks are African American, and
come from North American cohorts. Asians are pre-
dominantly Eastern Asian in C-Stride and CKD-JAC,
while in EQUAL, South Asians; however, the sample size
of South Asians may not be sufficient for stratified
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analyses. We, therefore, hope to include emerging stud-
ies from India and the African continent in the future.
Conclusion
In summary, this network will aid joint research in the
field of CKD around the globe. With an emerging infra-
structure to facilitate interactions among investigators,
the commitment of currently involved investigators to
ensure responsible use of the data, and a broadly defined
research agenda, we are confident that there will be on-
going development of new cohort studies around the
globe that will join iNET-CKD. This international net-
work will be in an exceptional position to validate find-
ings across geographical and national boundaries, to test
hypotheses and to generate new understanding of CKD
progression and its complications. These, in turn, can be
used to inform clinical trials, potentially serve as a
source of patients for clinical trials, and help to inform
health policy.
Additional files
Additional file 1: Table S1. Summary of study designs and primary
outcomes of interest. Provides an overview of the study designs and
primary outcomes of interest for each iNET-CKD Study. Abbreviations: CKD,
chronic kidney disease; ESRD, end-stage renal disease; CVD, cardiovascular
disease; PWV, pulse wave velocity. (TIF 635 kb)
Additional file 2: Table S2. Summary of baseline covariates,
measurements, and event ascertainment among participating studies.
Provides a summary of baseline covariates, study measurements, and
event ascertainment activities for each iNET-CKD study. Abbreviations:
IDMS Cr, IDMS-calibrated serum creatinine; ACR, urinary albumin-to-creatinine
ratio; PCR, urinary protein-to-creatinine ratio; CVD, cardiovascular disease;
BMI, body mass index. (TIF 1106 kb)
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